Human VEGF-D Quantikine ELISA Kit

Reduction of migration and invasion of 468LN cells by knocking down VEGF-D production:(A–C) Levels of VEGF-D knock down in 468LN cells was confirmed by three different methods, (A) qRT-PCR, (B) western blot and (C) ELISA. After VEGF-D knock down (KD) in 468LN cells, (D) migration, invasion and (E) proliferation significantly dropped as compared to scrambled knock down (SCR-KD) cells. (F) Addition of exogenous rVEGF-D or FBS increased both migration and invasion of VEGF-D knocked down 468LN cells. Bars represent mean (n = 4 in all cases except C, n = 6) ± SE, *,P<0.05; **,P<0.01. Image collected and cropped by CiteAb from the following open publication (//dx.plos.org/10.1371/journal.pone.0035094), licensed under a CC-BY license. Not internally tested by R&D Systems.

• Reactivity: Hu
• Applications: ELISA
• Conjugate: HRP

Human VEGF-D Quantikine ELISA Kit Summary

• Background: The Quantikine Human VEGF-D Immunoassay is a 4.5 hour solid phase ELISA designed to measure VEGF-D levels in cell culture supernates, serum, and plasma. It contains Sf 21-expressed, recombinant human VEGF-D and antibodies raised against the recombinant protein. Results obtained for naturally occurring human VEGF-D showed linear curves that were parallel to the standard curves obtain...ed using the kit standards. These results indicate that this kit can be used to determine relative mass values for natural human VEGF-D.
  Show More
• Specificity: Natural and recombinant human VEGF-D
• Source: N/A
• Assay Type: Solid Phase Sandwich ELISA
• Inter-Assay: See PDF Datasheet for details
• Intra-Assay: See PDF Datasheet for details
• Spike Recovery: See PDF Datasheet for details
• Sample Volume: See PDF Datasheet for details
• Gene: FIGF

Applications/Dilutions

• Dilutions:
  • ELISA
• Application Notes: No significant interference observed with available related molecules.

Packaging, Storage & Formulations

• Storage: Store the unopened product at 2 - 8 °C. Do not use past expiration date.

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for Human VEGF-D Quantikine ELISA Kit

• c-fos induced growth factor (vascular endothelial growth factor D)
• FIGF
• vascular endothelial growth factor D
• VEGFD
• VEGF-D
• VEGF-DVEGFDc-Fos-induced growth factor

Background

Vascular endothelial growth factor D (VEGF-D) is a homodimeric ligand of VEGF R3/Flt-4 and is synthesized with N- and C-terminal propeptides. Fully processed VEGF-D containing only the VEGF homology domain can additionally bind and activate VEGF R2/KDR/Flk-1. VEGF-D is expressed in adult lung, heart, muscle, and small intestine, and is most abundantly expressed in fetal lungs and skin. VEGF R3 is strongly expressed in lymphatic endothelial cells and is essential for regulation of the growth and differentiation of lymphatic endothelium. While VEGF-C is the critical ligand for VEGF R3 during embryonic lymphatic development, while VEGF-D is most active in neonatal lymphatic maturation and bone growth.

&#9888; WARNING: This product can expose you to chemicals including N,N-Dimethylforamide, which is known to the State of California to cause cancer. For more information, go to www.P65Warnings.ca.gov.

Publications for VEGF-D (DVED00)(36)

Publications using DVED00

• Chachaj, A;Stanimirova, I;Chabowski, M;Gomu?kiewicz, A;Hodurek, P;Glatzel-Pluci?ska, N;Olbromski, M;Piotrowska, A;Kuzan, A;Grzegrzó?ka, J;Ratajczak-Wielgomas, K;Nowak, A;Szahidewicz-Krupska, E;Wi?niewski, J;Bromke, MA;Podhorska-Oko?ów, M;Gamian, A;Janczak, D;Dzi?giel, P;Szuba, A; Sodium accumulation in the skin is associated with higher density of skin lymphatic vessels in patients with arterial hypertension Advances in medical sciences 2023-08-26 [PMID: 37639949] (Human)
• L Fornaro, G Musettini, P Orlandi, I Pecora, C Vivaldi, M Banchi, F Salani, E Fini, V Massa, S Catanese, F Cucchiara, M Lencioni, G Masi, E Vasile, G Bocci Early increase of plasma soluble VEGFR-2 is associated with clinical benefit from second-line treatment of paclitaxel and ramucirumab in advanced gastric cancer American journal of cancer research, 2022-07-15;12(7):3347-3356. 2022-07-15 [PMID: 35968330] (Human)
• I Wada, S Nakao, M Yamaguchi, Y Kaizu, M Arima, S Sawa, KH Sonoda Retinal VEGF-A Overexpression Is Not Sufficient to Induce Lymphangiogenesis Regardless of VEGF-C Upregulation and Lyve1+ Macrophage Infiltration Investigative Ophthalmology & Visual Science, 2021-10-04;62(13):17. 2021-10-04 [PMID: 34673901] (Human)
• MA Wyatt, SC Baumgarten, AL Weaver, CC Van Oort, B Fedyshyn, R Ruano, CC Shenoy, EAL Enninga Evaluating Markers of Immune Tolerance and Angiogenesis in Maternal Blood for an Association with Risk of Pregnancy Loss Journal of Clinical Medicine, 2021-08-14;10(16):. 2021-08-14 [PMID: 34441875] (Human)
• T Mashima, T Wakatsuki, N Kawata, MK Jang, A Nagamori, H Yoshida, K Nakamura, T Migita, H Seimiya, K Yamaguchi Neutralization of the induced VEGF-A potentiates the therapeutic effect of an anti-VEGFR2 antibody on gastric cancer in vivo Scientific Reports, 2021-07-23;11(1):15125. 2021-07-23 [PMID: 34302038] (Mouse)
• H Wada, M Suzuki, M Matsuda, Y Ajiro, T Shinozaki, S Sakagami, K Yonezawa, M Shimizu, J Funada, T Takenaka, Y Morita, T Nakamura, K Fujimoto, H Matsubara, T Kato, T Unoki, D Takagi, K Wada, M Wada, M Iguchi, N Masunaga, M Ishii, H Yamakage, T Kusakabe, A Yasoda, A Shimatsu, K Kotani, N Satoh-Asah, M Abe, M Akao, K Hasegawa Distinct Characteristics of VEGF-D and VEGF-C to Predict Mortality in Patients With Suspected or Known Coronary Artery Disease J Am Heart Assoc, 2020-04-22;9(9):e015761. 2020-04-22 [PMID: 32319336] (Human)
• TH Chin, CP Lin, SD Chang, HS Wang, HY Huang, YK Soong, HM Wu, PH Chu Application of non-invasive detection of peripheral vascular dysfunction in ovarian hyperstimulation syndrome (OHSS): A pilot study of clinical relevance Taiwan J Obstet Gynecol, 2019-05-01;58(3):354-358. 2019-05-01 [PMID: 31122524] (Human)
• M Hirose, A Matsumuro, T Arai, C Sugimoto, M Akira, M Kitaichi, LR Young, FX McCormack, Y Inoue Serum vascular endothelial growth factor-D as a diagnostic and therapeutic biomarker for lymphangioleiomyomatosis PLoS ONE, 2019-02-28;14(2):e0212776. 2019-02-28 [PMID: 30818375] (Human)
• N Chebib, F Archer, A Bobet-Erny, C Leroux, V Cottin Dysregulation of the endothelin pathway in lymphangioleiomyomatosis with no direct effect on cell proliferation and migration Sci Rep, 2018-10-02;8(1):14698. 2018-10-02 [PMID: 30279475] (Human)
• ECTD Nascimento, BG Baldi, AW Mariani, R Annoni, RA Kairalla, SP Pimenta, LFF da Silva, CRR Carvalho, M Dolhnikoff Immunohistological features related to functional impairment in lymphangioleiomyomatosis Respir. Res., 2018-05-08;19(1):83. 2018-05-08 [PMID: 29739412] (Human)
• Kumar N, Moideen K, Sivakumar S, Menon P, Viswanathan V, Kornfeld H, Babu S Tuberculosis-diabetes co-morbidity is characterized by heightened systemic levels of circulating angiogenic factors. J Infect, 2016-10-04;74(1):10-21. 2016-10-04 [PMID: 27717783] (Human)
• Human neural stem cell-induced endothelial morphogenesis requires autocrine/paracrine and juxtacrine signaling Sci Rep, 2016-07-04;6(0):29029. 2016-07-04 [PMID: 27374240] (Human)
• Kumar N, Banurekha V, Nair D, Babu S Circulating Angiogenic Factors as Biomarkers of Disease Severity and Bacterial Burden in Pulmonary Tuberculosis. PLoS ONE, 2016-01-04;11(1):e0146318. 2016-01-04 [PMID: 26727122] (Human)
• Sallinen H, Heikura T, Koponen J, Kosma V, Heinonen S, Yla-Herttuala S, Anttila M Serum angiopoietin-2 and soluble VEGFR-2 levels predict malignancy of ovarian neoplasm and poor prognosis in epithelial ovarian cancer. BMC Cancer, 2014-09-23;14(0):696. 2014-09-23 [PMID: 25245329] (Human)
• Weinkopff T, Mackenzie C, Eversole R, Lammie P Filarial excretory-secretory products induce human monocytes to produce lymphangiogenic mediators. PLoS Negl Trop Dis, 2014-07-10;8(7):e2893. 2014-07-10 [PMID: 25010672] (Human)
• Grepin R, Guyot M, Giuliano S, Boncompagni M, Ambrosetti D, Chamorey E, Scoazec J, Negrier S, Simonnet H, Pages G The CXCL7/CXCR1/2 axis is a key driver in the growth of clear cell renal cell carcinoma. Cancer Res, 2013-12-12;74(3):873-83. 2013-12-12 [PMID: 24335961] (Human)
• Braicu E, Fotopoulou C, Chekerov R, Richter R, Blohmer J, Kummel S, Stamatian F, Yalcinkaya I, Mentze M, Lichtenegger W, Sehouli J Role of serum concentration of VEGFR1 and TIMP2 on clinical outcome in primary cervical cancer: results of a companion protocol of the randomized, NOGGO-AGO phase III adjuvant trial of simultaneous cisplatin-based radiochemotherapy vs. carboplatin and paclitaxel containing sequential radiotherapy. Cytokine, 2013-02-14;61(3):755-8. 2013-02-14 [PMID: 23415672] (Human)
• Majumder M, Tutunea-Fatan E, Xin X, Rodriguez-Torres M, Torres-Garcia J, Wiebe R, Timoshenko AV, Bhattacharjee RN, Chambers AF, Lala PK Co-expression of alpha9beta1 integrin and VEGF-D confers lymphatic metastatic ability to a human breast cancer cell line MDA-MB-468LN. PLoS ONE, 2012-04-24;7(4):e35094. 2012-04-24 [PMID: 22545097] (Human)
• Clinical utility of diagnostic guidelines and putative biomarkers in lymphangioleiomyomatosis. Respir. Res., 2012-04-18;13(0):34. 2012-04-18 [PMID: 22513045] (Human)
• Dabora SL, Franz DN, Ashwal S, Sagalowsky A, DiMario FJ, Miles D, Cutler D, Krueger D, Uppot RN, Rabenou R, Camposano S, Paolini J, Fennessy F, Lee N, Woodrum C, Manola J, Garber J, Thiele EA Multicenter phase 2 trial of sirolimus for tuberous sclerosis: kidney angiomyolipomas and other tumors regress and VEGF- D levels decrease. PLoS ONE, 2011-09-06;6(9):e23379. 2011-09-06 [PMID: 21915260] (Human)
• Landt S, Wehling M, Heidecke H, Jeschke S, Korlach S, Stoblen F, Schmid P, Blohmer JU, Lichtenegger W, Sehouli J, Kummel S Prognostic significance of angiogenic factors in uterine cervical cancer. Anticancer Res., 2011-08-01;31(8):2589-95. 2011-08-01 [PMID: 21778309] (Human)
• Konings IR, de Jonge MJ, Burger H Phase I and pharmacological study of the broad-spectrum tyrosine kinase inhibitor JNJ-26483327 in patients with advanced solid tumours. Br. J. Cancer, 2010-09-07;103(7):987-92. 2010-09-07 [PMID: 20823884] (Human)
• Honda N, Jinnin M, Kajihara I, Makino T, Fukushima S, Ihn H Impaired lymphangiogenesis due to excess vascular endothelial growth factor-D/Flt-4 signalling in the skin of patients with systemic sclerosis. Br. J. Dermatol., 2010-10-01;163(4):776-80. 2010-10-01 [PMID: 20491763] (Human)
• Papiewska-Pajak I, Boncela J, Przygodzka P, Cierniewski CS Autocrine effects of VEGF-D on endothelial cells after transduction with AD-VEGF-D(DeltaNDeltaC). Exp. Cell Res., 2010-01-22;316(6):907-14. 2010-01-22 [PMID: 20096685] (Human)
• Glasgow CG, Avila NA, Lin JP, Stylianou MP, Moss J Serum vascular endothelial growth factor-D levels in patients with lymphangioleiomyomatosis reflect lymphatic involvement. Chest, 2009-05-01;135(5):1293-300. 2009-05-01 [PMID: 19420197] (Human)
• Toivanen PI, Nieminen T, Viitanen L, Alitalo A, Roschier M, Jauhiainen S, Markkanen JE, Laitinen OH, Airenne TT, Salminen TA, Johnson MS, Airenne KJ, Yla-Herttuala S Novel vascular endothelial growth factor D variants with increased biological activity. J. Biol. Chem., 2009-04-14;284(23):16037-48. 2009-04-14 [PMID: 19366703] (Human)
• Sorrentino A, Ferracin M, Castelli G, Biffoni M, Tomaselli G, Baiocchi M, Fatica A, Negrini M, Peschle C, Valtieri M Isolation and characterization of CD146+ multipotent mesenchymal stromal cells. Exp. Hematol., 2008-05-27;36(8):1035-46. 2008-05-27 [PMID: 18504067] (Human)
• Simiantonaki N, Jayasinghe C, Michel-Schmidt R, Peters K, Hermanns MI, Kirkpatrick CJ Hypoxia-induced epithelial VEGF-C/VEGFR-3 upregulation in carcinoma cell lines. Int. J. Oncol., 2008-03-01;32(3):585-92. 2008-03-01 [PMID: 18292935] (Human)
• Koponen JK, Kekarainen T, E Heinonen S, Laitinen A, Nystedt J, Laine J, Yla-Herttuala S Umbilical Cord Blood-derived Progenitor Cells Enhance Muscle Regeneration in Mouse Hindlimb Ischemia Model. Mol. Ther., 2007-09-18;15(12):2172-7. 2007-09-18 [PMID: 17878901] (Human)
• Lee CY, Tien HF, Hu CY, Chou WC, Lin LI Marrow angiogenesis-associated factors as prognostic biomarkers in patients with acute myelogenous leukaemia. Br. J. Cancer, 2007-09-11;97(7):877-82. 2007-09-11 [PMID: 17848952] (Human)
• Kholova I, Koota S, Kaskenpaa N, Leppanen P, Narvainen J, Kavec M, Rissanen TT, Hazes T, Korpisalo P, Grohn O, Yla-Herttuala S Adenovirus-mediated gene transfer of human vascular endothelial growth factor-d induces transient angiogenic effects in mouse hind limb muscle. Hum. Gene Ther., 2007-03-01;18(3):232-44. 2007-03-01 [PMID: 17362136] (Human)
• Laakkonen P, Waltari M, Holopainen T, Takahashi T, Pytowski B, Steiner P, Hicklin D, Persaud K, Tonra JR, Witte L, Alitalo K Vascular endothelial growth factor receptor 3 is involved in tumor angiogenesis and growth. Cancer Res., 2007-01-15;67(2):593-9. 2007-01-15 [PMID: 17234768] (Human)
• Kummel S, Eggemann H, Luftner D, Thomas A, Jeschke S, Zerfel N, Heilmann V, Emons G, Zeiser T, Ulm K, Kobl M, Korlach S, Schmid P, Sehouli J, Elling D, Blohmer JU Changes in the circulating plasma levels of VEGF and VEGF-D after adjuvant chemotherapy in patients with breast cancer and 1 to 3 positive lymph nodes. Anticancer Res., 2006-03-01;26(2):1719-26. 2006-03-01 [PMID: 16617567] (Human)
• Akahane M, Akahane T, Shah A, Okajima E, Thorgeirsson UP A potential role for vascular endothelial growth factor-D as an autocrine growth factor for human breast carcinoma cells. Anticancer Res., 2005-03-01;25(2):701-7. 2005-03-01 [PMID: 15868899] (Human)
• Fink AM, Kaltenegger I, Schneider B, Fruhauf J, Jurecka W Serum level of VEGF-D in patients with primary lymphedema. Lymphology, 2004-12-01;37(4):185-9. 2004-12-01 [PMID: 15693535] (Human)
• George ML, Tutton MG, Janssen F, Arnaout A, Abulafi AM, Eccles SA, Swift RI VEGF-A, VEGF-C, and VEGF-D in colorectal cancer progression. Neoplasia, 2001-09-01;3(5):420-7. 2001-09-01 [PMID: 11687953] (Human)

FAQs for VEGF-D (DVED00). (Showing 1 - 1 of 1 FAQs).

1. What is the difference between the Quantikine and Duoset ELISA kits?
   • Our Quantikine kits are fully optimized and validated for the sample types listed on the product specific webpage and datasheet, as this can vary between kits. Each kit is supplied ready to use with one pre-coated 96-well plate, a detection antibody directly conjugated to HRP, and all other necessary reagents. These kits are ideal for researchers who want the convenience of a ready to use and optimized ELISA product. Some of these kits are also available prepackaged in larger 6 and 50 plate sizes.Our DuoSet Kits, in contrast, are ELISA development kits containing the capture and detection antibody, the mass-value calibrated standard, and streptavidin-HRP to prepare approximately 5 or 15 plates. Ancillary reagents will need to be used/purchased, and for most kits, we will recommend one of our Ancillary Reagent Kits, which contain the reagents we use ourselves in-house. DuoSet kits are validated only for cell culture supernatant samples and therefore require further development and validation for accurate measurement in more complex samples such as serum and plasma. Our DuoSet Kits offer an economical, flexible alternative for the experienced ELISA user.

Bioinformatics

• Gene Symbol: FIGF